Analyst Research

Report Title Price
Provider: Pechala's Reports
$15.00
Provider: Reuters Investment Profile
$20.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Opexa Therapeutics Inc Announces Management Change-Form 8-K


Monday, 13 Aug 2012 08:30am EDT 

Opexa Therapeutics Inc reported in its Form 8-K that David E. Jorden, has been appointed as Acting Chief Financial Officer (CFO) of the Company effective August 15, 2012, with a term of office to serve at the discretion of the Board of Directors. Concurrent with assuming his new role as Acting Chief Financial Officer, Mr. Jorden will step down as Chair and member of the Board’s Audit Committee and as a member of the Governance and Nominating Committee, but will continue to serve as a Director. As Acting Chief Financial Officer, Mr. Jorden will serve as the Company's principal financial and accounting officer, to succeed in that position the Company's President and Chief Executive Officer (CEO), Neil K. Warma, who previously held the additional title of Acting Chief Financial Officer. 

Company Quote

1.56
-0.01 -0.64%
11 Jul 2014